Spots Global Cancer Trial Database for indolent systemic mastocytosis
Every month we try and update this database with for indolent systemic mastocytosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | NCT04910685 | Indolent System... Monoclonal Mast... | BLU-263 Placebo | 16 Years - | Blueprint Medicines Corporation | |
| Midostaurin in Indolent Systemic Mastocytosis | NCT01920204 | Indolent System... | Midostaurin, | 18 Years - | University Medical Center Groningen | |
| Midostaurin in Indolent Systemic Mastocytosis | NCT01920204 | Indolent System... | Midostaurin, | 18 Years - | University Medical Center Groningen | |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | NCT04910685 | Indolent System... Monoclonal Mast... | BLU-263 Placebo | 16 Years - | Blueprint Medicines Corporation | |
| Midostaurin in Indolent Systemic Mastocytosis | NCT01920204 | Indolent System... | Midostaurin, | 18 Years - | University Medical Center Groningen | |
| Treatment of Indolent Systemic Mastocytosis With PA101 | NCT02478957 | Mastocytosis Systemic Mastoc... Indolent System... | PA101 Placebo | 18 Years - 75 Years | Patara Pharma | |
| (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | NCT03731260 | Indolent System... | Avapritinib Placebo | 18 Years - | Blueprint Medicines Corporation | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 | NCT02808793 | Indolent System... | AK002 | 18 Years - 65 Years | Allakos Inc. | |
| Treatment of Indolent Systemic Mastocytosis With PA101 | NCT02478957 | Mastocytosis Systemic Mastoc... Indolent System... | PA101 Placebo | 18 Years - 75 Years | Patara Pharma | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | NCT04333108 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science | |
| Mast Cell Connect: A Registry for Patients With Mastocytosis | NCT02620254 | Mastocytosis | - | Blueprint Medicines Corporation | ||
| Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis | NCT03770273 | Indolent System... | sarilumab Placebo | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language | NCT03632811 | Cutaneous Masto... Indolent System... | A structured in... | 18 Years - | University Hospital, Toulouse | |
| Mast Cell Connect: A Registry for Patients With Mastocytosis | NCT02620254 | Mastocytosis | - | Blueprint Medicines Corporation | ||
| Midostaurin in Indolent Systemic Mastocytosis | NCT01920204 | Indolent System... | Midostaurin, | 18 Years - | University Medical Center Groningen | |
| Angioedema Biomarker Research Study | NCT06210698 | Angioedema Angioedemas, He... Urticaria Mastocytosis ACE Inhibitor-I... C1 Inhibitor De... Systemic Mastoc... Indolent System... | Venipuncture | 12 Years - 75 Years | Foundation For Rare Disease Research | |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | NCT05186753 | SSM Mastocytosis, I... Mastocytosis, S... Mastocytosis | Bezuclastinib T... Bezuclastinib T... Placebo Tablets | 18 Years - | Cogent Biosciences, Inc. | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis | NCT00814073 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
